[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][C][N][Branch1][Ring2][C][C][C][C][C][C][=C][C][C][=Branch1][C][=O][N][C][Ring1][=Branch1][=C][C][=C][Ring1][#Branch2]"}, {"from": "gpt", "value": "The molecule is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome,. It is manufactured by GlaxoSmithKline Pharmaceuticals.   Ropinirole was initially approved in 1997 by the FDA for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome.   In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole."}]